Dengue vaccines for travelers

Expert Review of Vaccines

Volumn 7, Issue 5, 2008, Pages 569-578

  Wilder Smith, Annelies ^a   Deen, Jacqueline L ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b International Vaccine Institute   (South Korea)

Author keywords

Dengue; Dengue vaccine; International travel; Risk of dengue in travelers

Indexed keywords

CHIMERIVAX DENGUE; DENGUE VACCINE;

AEDES; COST EFFECTIVENESS ANALYSIS; DENGUE; DRUG SAFETY; EMPORIATRICS; EPIDEMIC ENCEPHALITIS; FLAVIVIRUS; IMMUNOGENICITY; INFECTION RISK; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRAVEL; YELLOW FEVER;

ANIMALS; DENGUE VACCINES; DENGUE VIRUS; FLAVIVIRUS INFECTIONS; HUMANS; IMMUNIZATION; TRAVEL;

EID: 45849101684     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.5.569     Document Type: Review

References (86)

1. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 33(4), 330-342 (2002).
2. Wilder-Smith A, Schwartz E. Dengue in travelers. N. Engl. J. Med. 353(9), 924-932 (2005). • Summarizes current knowledge on issues of dengue in the context of international travelers.
3. Sharp TW, Wallace MR, Hayes CG et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am. J. Trop. Med. Hyg. 53(1), 89-94 (1995).
4. Sharp TW, DeFraites RF, Thornton SA, Burans JP, Wallace MR. Illness in journalists and relief workers involved in international humanitarian assistance efforts in Somalia, 1992-93. J. Travel Med. 2(2), 70-76 (1995).
5. Gambel JM, Drabick JJ, Swalko MA, Henchal EA, Rossi CA, Martinez-Lopez L. Dengue among United Nations mission in Haiti personnel, 1995: implications for preventive medicine. Mil. Med. 164(4), 300-302 (1999).
6. Cobelens FG, Groen J, Osterhaus AD, Leentvaar-Kuipers A, Wertheim-van Dillen PM, Kager PA. Incidence and risk factors of probable dengue virus infection among Dutch travellers to Asia. Trop. Med. Int. Health 7(4), 331-338 (2002).
7. Potasman I, Srugo I, Schwartz E. Dengue seroconversion among Israeli travelers to tropical countries. Emerg. Infect. Dis. 5(6), 824-827 (1999).
8. Steffen R, Heusser R, Machler R et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy. Bull. World Health Organ. 68(3), 313-322 (1990).
9. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 272(11), 885-889 (1994).
10. Stephan C, Allwinn R, Brodt HR, Knupp B, Preiser W, Just-Nubling G. Travel-acquired dengue infection: clinical spectrum and diagnostic aspects. Infection 30(4), 225-258 (2002).
11. O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin. Infect. Dis. 33(5), 603-609 (2001).
12. Stienlauf S, Segal G, Sidi Y, Schwartz E. Epidemiology of travel-related hospitalization. J. Travel Med. 12(3), 136-141 (2005).
13. Freedman D; The GeoSentinel Group. GeoSentinel: the Global Emerging Infections Sentinel Network of the International Society of Travel Medicine. J. Travel Med. 6, 94-98 (1999).
14. Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N. Engl. J. Med. 354(2), 119-130 (2006). • Describes how dengue is the most common cause of fever in travelers returning from South-East Asia.
15. Schwartz E, Weld L, Wilder-Smith A. Seasonality, annual trends, and characteristics of dengue in ill returned travelers (1997-2006). Emerging Infect. Dis. (In press) (2008).
16. Jelinek T, Muhlberger N, Harms G et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin. Infect. Dis. 35(9), 1047-1052 (2002).
17. Wichmann O, Mühlberger N, Jelinek T. Dengue - the underestimated risk in travellers. Dengue Bull. 27, 126-137 (2003).
18. Wilson ME, Freedman DO. Etiology of travel-related fever. Curr. Opin. Infect. Dis. 20(5), 449-453 (2007).
19. Schwartz E, Mendelson E, Sidi Y. Dengue fever among travelers. Am. J. Med. 101(5), 516-520 (1996).
20. Jensenius M, Gundersen SG, Vene S, Bruu AL. [Dengue fever imported to Norway. Serologically confirmed cases 1991-96]. Tidsskr. Nor. Laegeforen. 117(29), 4230-4233 (1997).
21. Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infection. J. Clin. Virol. 38(1), 1-6 (2007).
22. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5(7), 518-528 (2007).
23. Guzman MG, Kouri G. Dengue: an update. Lancet Infect. Dis. 2(1), 33-42 (2002). • Excellent review article on dengue.
24. Lum LC, Lam SK, George R, Devi S. Fulminant hepatitis in dengue infection. Southeast Asian J. Trop. Med. Public Health 24(3), 467-471 (1993).
25. Ling LM, Wilder-Smith A, Leo YS. Fulminant hepatitis in dengue haemorrhagic fever. J. Clin. Virol. 38(3), 265-268 (2007).
26. Seet RC, Lim EC, Wilder-Smith EP. Acute transverse myelitis following dengue virus infection. J. Clin. Virol. 35(3), 310-312 (2006).
27. Solomon T, Dung NM, Vaughn DW et al. Neurological manifestations of dengue infection. Lancet 355(9209), 1053-1059 (2000).
28. Wilder-Smith A, Tambyah PA. Severe dengue virus infection in travelers. J. Infect. Dis. 195(8), 1081-1083 (2007). • Elaborates on possible reasons why dengue hemorrhagic fever is not frequently observed in adult travelers.
29. Wichmann O, Gascon J, Schunk M et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J. Infect. Dis. 195(8), 1089-1096 (2007).
30. Gamble J, Bethell D, Day NP et al. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? Clin. Sci. (Lond.) 98(2), 211-216 (2000).
31. Rosen L. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 26(3), 337-343 (1977).
32. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11(3), 480-496 (1998).
33. Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181(1), 2-9 (2000).
34. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42(5), 311-328 (1970).
35. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38(1), 172-180 (1988).
36. Guzman MG, Kouri G, Valdes L et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152(9), 793-799 (2000).
37. Kuhn RJ, Zhang W, Rossmann MG et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108(5), 717-725 (2002).
38. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140(4), 527-533 (1979).
39. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev. Infect. Dis. 11(Suppl. 4), S830-S839 (1989).
40. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J. Immunol. 132(3), 1529-1532 (1984).
41. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by nonneutralizing antibody. J. Exp. Med. 146(1), 201-217 (1977).
42. Halstead SB. Immune enhancement of viral infection. Prog. Allergy 31, 301-364 (1982).
43. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud. Publica. 11(4), 223-227 (2002).
44. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol. Cell Biol. 85(1), 43-45 (2007).
45. Mongkolsapaya J, Dejnirattisai W, Xu XN et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9(7), 921-927 (2003).
46. Dong T, Moran E, Vinh Chau N et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS ONE 2(12), e1192 (2007).
47. Mongkolsapaya J, Duangchinda T, Dejnirattisai W et al. T cell responses in dengue hemorrhagic fever: are crossreactive T cells suboptimal? J. Immunol. 176(6), 3821-3829 (2006).
48. Avirutnan P, Punyadee N, Noisakran S et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193(8), 1078-1088 (2006).
49. Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, Russell KL. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J. Infect. Dis. 191(6), 1000-1004 (2005).
50. Monath TP. Dengue and yellow fever - challenges for the development and use of vaccines. N. Engl. J. Med. 357(22), 2222-2225 (2007). • Highlights all the issues and challenges of developing a dengue vaccine.
51. Halstead SB, Deen J. The future of dengue vaccines. Lancet 360(9341), 1243-1245 (2002).
52. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull. World Health Organ. 83(4), 308-314 (2005).
53. Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin. Infect. Dis. 18(5), 387-394 (2005).
54. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 363(9426), 2073-2075 (2004).
55. Kitchener S, Nissen M, Nasveld P et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24(9), 1238-1241 (2006).
56. Halstead SV, Gubler D. Dengue vaccines. In: Vaccines. Plotkin S, Orenstein W, Offit P (Eds). Elsevier, Oxford, UK 1155-1161 (2008).
57. Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23(2), 99-109 (2004).
58. Chanthavanich P, Luxemburger C, Sirivichayakul C et al. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am. J. Trop. Med. Hyg. 75(1), 26-28 (2006).
59. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl. 2), 44-47 (2000).
60. Kanesa-Thasan N, Sun W, Kim-Ahn G et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19(23-24), 3179-3188 (2001).
61. Guirakhoo F, Weltzin R, Chambers TJ et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74(12), 5477-5485 (2000).
62. Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J. Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice. J. Gen. Virol. 87(Pt 11), 3131-3140 (2006).
63. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7-8), 1004-1018 (2002).
64. McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis. 197(5), 693-697 (2008).
65. Deauvieau F, Sanchez V, Balas C et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am. J. Trop. Med. Hyg. 76(1), 144-154 (2007).
66. Monath TP, Myers GA, Beck RA et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33(3), 131-144 (2005).
67. Guirakhoo F, Zhang Z, Myers G et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol. 78(18), 9998-10008 (2004).
68. Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256-3263 (2005).
69. Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2(2), 60-67 (2006).
70. Kinney RM, Butrapet S, Chang GJ et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230(2), 300-308 (1997).
71. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70(6), 3930-3937 (1996).
72. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77(2), 1653-1657 (2003).
73. Durbin AP, Whitehead SS, McArthur J et al. rDEN4δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191(5), 710-718 (2005).
74. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol. 19(1), 10-32 (2006).
75. Markoff L, Pang X, Houng HS et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76(7), 3318-3328 (2002).
76. Putnak R, Barvir DA, Burrous JM et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174(6), 1176-1184 (1996).
77. Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev. Panam. Salud. Publica. 21(4), 254-260 (2007).
78. Putnak R, Fuller J, VanderZanden L, Innis BL, Vaughn DW. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am. J. Trop. Med. Hyg. 68(4), 469-476 (2003).
79. Hatch S, Mathew A, Rothman A. Dengue vaccine: opportunities and challenges. IDrugs 11(1), 42-45 (2008).
80. Monath TP, Kanesa-Thasan N, Guirakhoo F et al. Recombination and flavivirus vaccines: a commentary. Vaccine 23(23), 2956-2958 (2005). • Provides good arguments for the benefit of live vaccines.
81. Deen JL. Editorial: the challenge of dengue vaccine development and introduction. Trop. Med. Int. Health 9(1), 1-3 (2004).
82. McMahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25(10), 1727-1734 (2007).
83. Monath TP, Cetron MS, McCarthy K et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin. 1(5), 207-214 (2005).
84. Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358(9276), 98-104 (2001).
85. World Tourism Organization www.unwto.org
86. Pediatric Dengue Vaccine Initiative www.pdvi.org